Citations

Clear

6273 citation(s) found for "To, Andrew".

Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.
Palumbo, Antonio, Chanan‐Khan, Asher , Mateos, María‐Victoria , Qi, Ming , Schecter, Jordan M. , Amin, Himal, Qin, Xiang , Deraedt, William , Ahmadi, Tahamtan , Spencer, Andrew , Sonneveld, Pieter , Weisel, Katja C , Nooka, Ajay K. , Masszi, Tamás , Beksaç, Meral , Špıčka, Ivan , Hungria, Vânia , Mark, Tomer M , Qi, Ming

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: LBA4-LBA4

10.1200/jco.2016.34.15_suppl.lba4 Get It

Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline
Bekelman, Justin E. , Pisansky, Thomas M. , Finelli, Antonio , Feifer, Andrew , Nguyen, Paul L. , Loblaw, D.A., Tagawa, Scott T. , Gillessen, Silke , Morgan, Todd M. , Liu, Glenn , Vapiwala, Neha , Haluschak, John J., Stephenson, Andrew J. , Touijer, Karim, Kungel, Terry, Freedland, Stephen J. , Loblaw, D Andrew, Stephenson, Andrew, Morgan, Todd M , Tagawa, Scott T , Rumble, R. Bryan , Chen, Ronald C.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 32 | Pages: 3251-3258

10.1200/jco.18.00606 | PMID 30183466 Get It

Purpose In April 2017, the American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology released a joint evidence-based practice guideline on clinically localized prostate cancer. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. Methods The Clinically Localized Prostate Cancer guideline was reviewed for developmental rigor by methodologists. An ASCO Expert Panel then reviewed the content and the recommendations. Results The ASCO Expert Panel determined that the recommendations from the Clinically Localized Prostate Cancer guideline were clear, thorough, and based upon the most relevant scientific evidence. ASCO endorsed the Clinically Localized Prostate Cancer guideline except for two recommendations on cryosurgery. The two recommendations covering cryosurgery were not endorsed because the panel found that there is insufficient evidence to support the use of cryotherapy in this setting. Recommendations The ASCO Expert Panel endorsed all but two of the original guideline recommendations as written and offered a series of discussion points to guide practice.
SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma.
Riedel, Richard F. , Brigman, Brian E. , Attia, Steven , Meyer, Christian F. , Schuetze, Scott M. , Dickson, Mark A. , Hartner, Lee , Tinoco, Gabriel , Tine, Brian Andrew Van, Wagner, Andrew J. , Kirsch, David G. , Riedel, Richard F , Tinoco, Gabriel , Mowery, Yvonne Marie , Ballman, Karla V. , Burgess, Melissa , Chmielowski, Bartosz , Milhem, Mohammed , Reinke, Denise K.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS11588-TPS11588

10.1200/jco.2018.36.15_suppl.tps11588 Get It

Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).
Ravi, Vinod , Chawla, Sant P. , Attia, Steven , Riedel, Richard F. , Thornton, Katherine A., Mallick, Atrayee Basu , Davis, Darren W. , Cervantes, Mario, Liu, Wen , Zhu, Keyi, Alvarez, Delia, Theuer, Charles P. , Tap, William D. , Jones, Robin L. , Maki, Robert G. , Maki, Robert G , Riedel, Richard F , Jones, Robin L , Brohl, Andrew S. , Liebner, David A. , Zhu, Keyi , Robinson, Steven I. , Penel, Nicolas , Stacchiotti, Silvia

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e23570-e23570

10.1200/jco.2018.36.15_suppl.e23570 Get It

Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.
Gounder, Mrinal M. , Somaiah, Neeta , Attia, Steven , Chawla, Sant P. , Villalobos, Víctor M. , Riedel, Richard F. , Wagner, Andrew J. , Mudenda, Boyd, Sadanowicz, Mara , Shah, Jatin J., Shacham, Sharon, Kauffman, Michael , Razak, Albiruni Ryan Abdul, Riedel, Richard F , Chmielowski, Bartosz , Burgess, Melissa , Schwartz, Gary K. , Mehren, Margaret von , Choy, Edwin , Verma, Shailendra , Li, Lingling

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 11512-11512

10.1200/jco.2018.36.15_suppl.11512 Get It

Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).
Gounder, Mrinal M. , Mahoney, Michelle R., Tine, Brian Andrew Van, Ravi, Vinod , Attia, Steven , Deshpande, Hari A. , Conry, Robert M. , Movva, Sujana , Pishvaian, Michael J. , Crawford, Jeffrey , Sabagh, Tarek, Tap, William D. , Lefkowitz, Robert A. , Agaram, Narasimhan P. , Wright, John Joseph, Gupta, Abha A. , Milhem, Mohammed , Maki, Robert G. , Dueck, Amylou C. , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 11500-11500

10.1200/jco.2018.36.15_suppl.11500 Get It

Addressing unmet medical needs in maintenance treatment for newly diagnosed multiple myeloma (NDMM).
Beksaç, Meral , Hájek, Roman , Mateos, María‐Victoria , Spencer, Andrew , Iida, Shinsuke , Farias, Danielle de, Labotka, Richard, Skácel, Tomáš, Palumbo, Antonio , Kumar, Shaji , Hajek, Roman , Chng, Wee Joo , Weisel, Katja C , Lonial, Sagar , Dimopoulos, Meletios Α.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e20049-e20049

10.1200/jco.2018.36.15_suppl.e20049 Get It

Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).
Chen, Robert W., Ansell, Stephen M. , Gallamini, Andrea , Grigg, Andrew , Sureda, Anna M., Feldman, Tatyana , Özdemir, Evren , Offner, Fritz , Engley, Gerald, Fenton, Keenan , Lee, Shih-Yuan, Jolin, Hina, Gautam, Ashish , Hutchings, Martin , Connors, Joseph M. , Savage, Kerry J. , Collins, Graham P. , Sureda, Anna , Ghosh, Nilanjan , Fosså, Alexander

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 7539-7539

10.1200/jco.2018.36.15_suppl.7539 Get It

A SU2C catalyst randomized phase II trial of pembrolizumab with or without paricalcitol in patients with stage IV pancreatic cancer who have been placed in best possible response.
Borazanci, Erkut , Jameson, Gayle , Downes, Michael , Truitt, Morgan , Patel, Hitendra , Lowy, Andrew M. , Roe, Denise J. , Ansaldo, Karen, Barrett, Michael T. , Korn, Ronald L. , Caldwell, Lana, Slethaug, Gavin, Hultsch, Rolf, Han, Haiyong , Engelthaler, David M. , Lenkiewics, Elizabeth, Hoff, Daniel D. Von , Borazanci, Erkut , Chung, Vincent , Evans, Ronald M. , Patel, Hitendra, Pearson, Talima

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS4154-TPS4154

10.1200/jco.2018.36.15_suppl.tps4154 Get It